Depot-medroxyprogesterone acetate and endothelial function before and after acute oral, vaginal, and transdermal estradiol treatment

Hypertension

Volumn 57, Issue 4, 2011, Pages 819-824

  Torgrimson, Britta N ^a   Meendering, Jessica R ^a   Kaplan, Paul F ^a,b   Minson, Christopher T ^a  

^a UNIVERSITY OF OREGON   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

contraceptive; endothelial function; endothelin 1; estrogen; estrone; progesterone

Indexed keywords

BIOLOGICAL MARKER; DEPOT MEDROXYPROGESTERONE ACETATE; ENDOTHELIN 1; ESTRADIOL; ESTRONE; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR RISK; ENDOTHELIUM; FEMALE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; TRANSDERMAL PATCH; ULTRASOUND; VAGINA RING; VASODILATATION;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BLOOD FLOW VELOCITY; BLOOD PRESSURE; BRACHIAL ARTERY; CONTRACEPTIVE AGENTS, FEMALE; DRUG ADMINISTRATION ROUTES; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGENS; ESTRONE; FEMALE; HEART RATE; HUMANS; IMMUNOASSAY; LINEAR MODELS; MEDROXYPROGESTERONE ACETATE; VASODILATION;

EID: 79953203585     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.163386     Document Type: Article

References (37)

1. Jeppsson S, Gershagen S, Johansson EDB, Rannevik G. Plasma-levels of medroxyprogesterone acetate (MPA), sex-hormone binding globulin, gonadal-steroids, gonadotropins and prolactin in women during long-term use of depo-mpa (depo-provera). Contracept Deliv Sys. 1982;3:102-102.
2. Cundy T, Ames R, Horne A. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J Clin Endocrin Metab. 2003;88:78-81. (Pubitemid 36115146)
3. English J, Jacobs L, Green G, Andrews T. Effect of the menstrual cycle on endothelium-dependent vasodilation of the brachial artery in normal young women. Am J Cardiol. 1998;82:256-261.
4. Gilligan D, Badar D, Panza J, Quyyumi A, Cannon R III. Acute vascular effects of estrogen in postmenopausal women. Circulation. 1994;90: 786-791. (Pubitemid 24242746)
5. Hashimoto M, Akishita M, Eto M, Ishikawa M, Kozaki K, Toba K, Sagara Y, Taketani Y, Orimo H, Ouchi Y. Modulation of endotheliumdependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation. 1995;92:3431-3435.
6. Herrington DM, Espeland MA, Crouse JR III, Robertson J, Riley WA, McBurnie MA, Burke GL. Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler Thromb Vasc Biol. 2001;21:1955-1961. (Pubitemid 34219747)
7. Kawano H, Motoyama T, Kugiyama K, Hirashima O, Ohgushi M, Yoshimura M, Ogawa H, Okumura K, Yasue H. Menstrual cyclic variation of endothelium-dependent vasodilation of the brachial artery: possible role of estrogen and nitric oxide. Proc Assoc Am Physicians. 1996;108:473-480.
8. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creager MA. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 1994;121:936-941. (Pubitemid 24370856)
9. Merki-Feld GS, Keller PJ. Decrease in endothelin-1 plasma levels during the menstrual cycle and after ethinylestradiol treatment. Ann Intern Med. 1999;131:394. (Pubitemid 29424637)
10. Polderman KH, Stehouwer CD, van Kamp GJ, Dekker GA, Verheugt FW, Gooren LJ. Influence of sex hormones on plasma endothelin levels. Ann Intern Med. 1993;118:429-432. (Pubitemid 23081052)
11. Ylikorkala O, Orpana A, Puolakka J, Pyörälä T, Viinikka L. Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. J Clin Endocrinol Metab. 1995;80:3384-3387.
12. The Writing Group for the Pepi Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (Pepi) Trial. JAMA. 1995;273:199-208.
13. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the lipid research clinics program follow-up study. Circulation. 1987;75:1102-1109. (Pubitemid 17081015)
14. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196-1204.
15. Giraud GD, Morton MJ, Wilson RA, Burry KA, Speroff L. Effects of estrogen and progestin on aortic size and compliance in postmenopausal women. Am J Obstet Gynecol. 1996;174:1708-1717; discussion 1717-1708.
16. Kawano H, Motoyama T, Hirai N, Yoshimura T, Kugiyama K, Ogawa H, Okamura H, Yasue H. Effect of medroxyprogesterone acetate plus estradiol on endothelium-dependent vasodilation in postmenopausal women. Am J Cardiol. 2001;87:238-240, A239. (Pubitemid 32057245)
17. Sullivan JM, Shala BA, Miller LA, Lerner JL, Mcbrayer JD. Progestin enhances vasoconstrictor responses in postmenopausal women receiving estrogen replacement therapy. Menopause. 1995;2:193-199.
18. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation. 2001;104:1773-1778. (Pubitemid 32963341)
19. Meendering JR, Torgrimson BN, Miller NP, Kaplan PF, Minson CT. Estrogen, medroxyprogesterone acetate, endothelial function, and biomarkers of cardiovascular risk in young women. Am J Physiol Heart Circ Physiol. 2008;294:H1630-H1637. (Pubitemid 351490592)
20. Sorensen MB, Collins P, Ong PJ, Webb CM, Hayward CS, Asbury EA, Gatehouse PD, Elkington AG, Yang GZ, Kubba A, Pennell DJ. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance. Circulation. 2002;106:1646-1651.
21. Rossi R, Nuzzo A, Origliani G, Modena MG. Prognostic role of flowmediated dilation and cardiac risk factors in post-menopausal women. J Am Coll Cardiol. 2008;51:997-1002. (Pubitemid 351318128)
22. Pyke KE, Dwyer EM, Tschakovsky ME. Impact of controlling shear rate on flow-mediated dilation responses in the brachial artery of humans. J Appl Physiol. 2004;97:499-508. (Pubitemid 38963116)
23. Naylor LH, Weisbrod CJ, O'Driscoll G, Green DJ. Measuring peripheral resistance and conduit arterial structure in humans using Doppler ultrasound. J Appl Physiol. 2005;98:2311-2315. (Pubitemid 40726930)
24. Pyke KE, Tschakovsky ME. The relationship between shear stress and flow-mediated dilatation: Implications for the assessment of endothelial function. J Physiol. 2005;568:357-369. (Pubitemid 41555444)
25. Woodman RJ, Playford DA, Watts GF, Cheetham C, Reed C, Taylor RR, Puddey IB, Beilin LJ, Burke V, Mori TA, Green D. Improved analysis of brachial artery ultrasound using a novel edge-detection software system. J Appl Physiol. 2001;91:929-937. (Pubitemid 32681129)
26. Zeni Hoch A, Dempsey RL, Carrera GF, Wilson CR, Chen EH, Barnabei VM, Sandford PR, Ryan TA, Gutterman DD. Is there an association between athletic amenorrhea and endothelial cell dysfunction? Med Sci Sports Exerc. 2003;35:377-383. (Pubitemid 36278762)
27. Kalantaridou SN, Naka KK, Papanikolaou E, Kazakos N, Kravariti M, Calis KA, Paraskevaidis EA, Sideris DA, Tsatsoulis A, Chrousos GP, Michalis LK. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab. 2004;89:3907-3913. (Pubitemid 39071493)
28. Mercuro G, Zoncu S, Saiu F, Mascia M, Melis GB, Rosano GM. Menopause induced by oophorectomy reveals a role of ovarian estrogen on the maintenance of pressure homeostasis. Maturitas. 2004;47:131-138. (Pubitemid 38130195)
29. vanderSchouw YT, vanderGraaf Y, Steyerberg EW, Eijkemans MJC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet. 1996;347:714-718. (Pubitemid 26085645)
30. Koh K, Jin D, Yang S, Lee S, Hwang H, Kang M, Kim W, Kim D, Choi I, Shin E. Vascular effects of synthetic or natural progestogen combined with conjugated equine estrogen in healthy post-menopausal women. Circulation. 2001;103:1961-1966. (Pubitemid 32322223)
31. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation. 2002;105:1436-1439. (Pubitemid 34263274)
32. Hasdai D, Lerman A. The atherogenic potential of endothelin. Coron Artery Dis. 1995;6:901-904. (Pubitemid 26115967)
33. Schiffrin EL, Touyz RM. Vascular biology of endothelin. J Cardiovasc Pharmacol. 1998;32(suppl 3):S2-S13. (Pubitemid 29019746)
34. Warner TD. Relationships between the endothelin and nitric oxide pathways. Clin Exp Pharmacol Physiol. 1999;26:247-252. (Pubitemid 29128024)
35. Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension. 1996;28:652-655. (Pubitemid 26327964)
36. Selles J, Polini N, Alvarez C, Massheimer V. Novel action of estrone on vascular tissue: Regulation of nos and cox activity. Steroids. 2005;70: 251-256. (Pubitemid 40387379)
37. Maffei S, Mercuri A, Zucchelli GC, Vassalle C. Estrogen therapy effects on different vasoactive factors in recent postmenopausal healthy women. Int J Cardiol. 2006;107:194-199. (Pubitemid 43075232)